These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 29701840)
1. A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge. Carroll TD; Jegaskanda S; Matzinger SR; Fritts L; McChesney MB; Kent SJ; Fairman J; Miller CJ J Infect Dis; 2018 Aug; 218(6):856-867. PubMed ID: 29701840 [TBL] [Abstract][Full Text] [Related]
2. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978 [TBL] [Abstract][Full Text] [Related]
3. Age at Vaccination and Timing of Infection Do Not Alter Vaccine-Associated Enhanced Respiratory Disease in Influenza A Virus-Infected Pigs. Souza CK; Rajão DS; Loving CL; Gauger PC; Pérez DR; Vincent AL Clin Vaccine Immunol; 2016 Jun; 23(6):470-482. PubMed ID: 27030585 [TBL] [Abstract][Full Text] [Related]
4. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses. Abente EJ; Rajao DS; Santos J; Kaplan BS; Nicholson TL; Brockmeier SL; Gauger PC; Perez DR; Vincent AL J Virol; 2018 Nov; 92(22):. PubMed ID: 30185589 [TBL] [Abstract][Full Text] [Related]
6. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization. Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A Front Immunol; 2019; 10():646. PubMed ID: 30984200 [TBL] [Abstract][Full Text] [Related]
7. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Lei H; Peng X; Jiao H; Zhao D; Ouyang J Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406 [TBL] [Abstract][Full Text] [Related]
8. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Budimir N; de Haan A; Meijerhof T; Gostick E; Price DA; Huckriede A; Wilschut J Influenza Other Respir Viruses; 2013 Nov; 7(6):1202-9. PubMed ID: 24102979 [TBL] [Abstract][Full Text] [Related]
9. Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines. Rajão DS; Chen H; Perez DR; Sandbulte MR; Gauger PC; Loving CL; Shanks GD; Vincent A J Gen Virol; 2016 Jul; 97(7):1489-1499. PubMed ID: 27031847 [TBL] [Abstract][Full Text] [Related]
10. Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Harris K; Ream R; Gao J; Eichelberger MC Virol J; 2011 May; 8():251. PubMed ID: 21600020 [TBL] [Abstract][Full Text] [Related]
11. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102 [TBL] [Abstract][Full Text] [Related]
12. Heterologous prime-boost H1N1 vaccination exacerbates disease following challenge with a mismatched H1N2 influenza virus in the swine model. Pliasas VC; Neasham PJ; Naskou MC; Neto R; Strate PG; North JF; Pedroza S; Chastain SD; Padykula I; Tompkins SM; Kyriakis CS Front Immunol; 2023; 14():1253626. PubMed ID: 37928521 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates. Boonnak K; Paskel M; Matsuoka Y; Vogel L; Subbarao K Vaccine; 2012 Aug; 30(38):5603-10. PubMed ID: 22789506 [TBL] [Abstract][Full Text] [Related]
14. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies. Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855 [TBL] [Abstract][Full Text] [Related]
15. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017 [TBL] [Abstract][Full Text] [Related]
16. Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Straight TM; Ottolini MG; Prince GA; Eichelberger MC Virol J; 2008 Mar; 5():44. PubMed ID: 18355405 [TBL] [Abstract][Full Text] [Related]